Research across Stroke
Related studies from across the Stroke family.
5 trials tracked for post-stroke spasticity: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 97 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Botulinum toxin type A has been shown to reduce muscle tone in various muscle groups following a stroke. In the gastrocnemius-soleus complex, treatment resulted in mean Modified Ashworth Scale (MAS) score reductions of -0.8 to -1.0 at week 4 1. Additionally, over 56% to 66% of patients achieved a 1 or 2 grade reduction in MAS scores for the gastrocnemius-soleus complex 1, and between 61% and 72% achieved similar reductions in the soleus muscle.
Specific upper extremity improvements were observed with Botulinum toxin type A. Studies demonstrated significant reductions in wrist flexor muscle tone (MAS) at weeks 6 and 12 (p<0.0001) 3. Furthermore, treatment with GSK1358820 resulted in MAS score reductions across the elbow, wrist, finger, and thumb flexors by week 12 2, with mean changes ranging from -0.59 to -1.12 2.
Clinical outcomes associated with Botulinum toxin interventions include improvements in functional scales. Patients reported improved Global Assessment Scale (GAS) scores at weeks 6 and 12 3. Treatment with GSK1358820 also demonstrated mean reductions in Disability Assessment Scale (DAS) scores for the primary measure [-0.49 to -0.82] 4, as well as improvements in Physician's Rating Score (PRS) and Clinical Global Impression (CGI) of functional disability 5.
AI synthesis of 5 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Stroke family.